Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $101.66 USD
Change Today -0.76 / -0.75%
Volume 2.5M
JNJ On Other Exchanges
Symbol
Exchange
New York
Xetra
Mexico
Sao Paulo
Bogota
As of 12:51 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

johnson & johnson (JNJ) Key Developments

Johnson & Johnson Announces Boar Changes

Johnson & Johnson announced that the decision of Stephen J. Cosgrove, Controller and Chief Accounting Officer of the company, to retire in October 2015. Upon Mr. Cosgrove's retirement, Ronald A. Kapusta will become Controller and Chief Accounting Officer of the company. Mr. Kapusta, 56, joined the company in 1992 and held a number of finance positions within the company's Consumer segment over the next nine years, including Operations Controller for the company's former subsidiary, McNeil Consumer Products Company, and Vice President, Finance, Worldwide Nutritionals. From 2001 to 2006, Mr. Kapusta served as Vice President, Finance for the Registrant's former subsidiary, Ortho-Clinical Diagnostics Inc., and then Vice President, Finance for the DePuy Orthopaedics Inc.

Johnson & Johnson Agrees to Pay About $7.8 Million to Settle A 71/2-Year-Old Lawsuit

Johnson & Johnson has agreed to pay about $7.8 million to settle a 71/2-year-old lawsuit by the state over how the company had marketed its popular anti-psychotic Risperdal to Arkansas doctors. Of that amount, $2 million will go to the Texas law firm that represented Arkansas in the Medicaid-fraud and deceptive-marketing lawsuit initiated in November 2007. The legal-services payment required the approval of Pulaski County Circuit Judge Tim Fox, who presided over the litigation. He signed off on the payment agreement in a two-page ruling that also described the state's settlement with the drugmaker. The judge had ordered the sides to attempt mediation earlier this month. The remaining $5,750,000 payout to the state is less than 1% of the $1.2 billion fine that had been imposed on Johnson & Johnson after a 12-day trial three years ago in which a Pulaski County jury found that the company, through its Janssen Pharmaceutical subsidiary, had committed Medicaid fraud and violated the state Deceptive Trade Practices Act in its labeling and marketing of Risperdal.

Johnson & Johnson Presents at BioEquity Europe 2015, May-19-2015 11:00 AM

Johnson & Johnson Presents at BioEquity Europe 2015, May-19-2015 11:00 AM. Venue: InterContinental Vienna, Vienna, Austria. Speakers: Jeanne Bolger, Vice President of Venture Investments.

Johnson & Johnson - Special Call

Johnson & Johnson - Special Call

Johnson & Johnson Presents at International Business Forum 14th Annual MedTech Investing Conference, May-06-2015

Johnson & Johnson Presents at International Business Forum 14th Annual MedTech Investing Conference, May-06-2015. Venue: Loews Minneapolis Hotel, 601, 1st Ave North, Minneapolis, MN 55403, United States. Presentation Date & Speakers: May-06-2015, Susan E Morano, Vice President of Business Development, Global Surgery Group.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
JNJ:US $101.65 USD -0.77

JNJ Competitors

Market data is delayed at least 15 minutes.

Company Last Change
General Electric Co $27.69 USD -0.035
Novartis AG SFr.98.10 CHF +0.05
Pfizer Inc $34.37 USD +0.01
Roche Holding AG SFr.277.90 CHF -1.30
Procter & Gamble Co/The $80.18 USD -0.23
View Industry Companies
 

Industry Analysis

JNJ

Industry Average

Valuation JNJ Industry Range
Price/Earnings 18.6x
Price/Sales 3.9x
Price/Book 4.2x
Price/Cash Flow 18.1x
TEV/Sales 3.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact JOHNSON & JOHNSON, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.